161 related articles for article (PubMed ID: 29953319)
21. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
[TBL] [Abstract][Full Text] [Related]
22. Cytokine immunotrapping: an assay to study the kinetics of production and consumption or degradation of human interferon-gamma.
Akdiş AC; Towbin H; Libsig P; Motz J; Alkan SS
J Immunol Methods; 1995 Jun; 182(2):251-61. PubMed ID: 7790729
[TBL] [Abstract][Full Text] [Related]
23. Gradual Increase of FcγRIIIa/CD16a Expression and Shift toward IFN-γ Secretion during Differentiation of CD56
Lajoie L; Congy-Jolivet N; Bolzec A; Thibault G
Front Immunol; 2017; 8():1556. PubMed ID: 29209315
[TBL] [Abstract][Full Text] [Related]
24. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
[TBL] [Abstract][Full Text] [Related]
25. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype.
Wing MG; Waldmann H; Isaacs J; Compston DA; Hale G
Ther Immunol; 1995 Aug; 2(4):183-90. PubMed ID: 9358610
[TBL] [Abstract][Full Text] [Related]
26. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
27. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
28. Effects of an FcγRIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies.
Stein MM; Hrusch CL; Sperling AI; Ober C
Genes Immun; 2019 Jul; 20(6):462-472. PubMed ID: 29977032
[TBL] [Abstract][Full Text] [Related]
29. Late-Onset Disseminated Mycobacterium avium intracellulare Complex Infection (MAC), Cerebral Toxoplasmosis and Salmonella Sepsis in a German Caucasian Patient with Unusual Anti-Interferon-Gamma IgG1 Autoantibodies.
Hanitsch LG; Löbel M; Müller-Redetzky H; Schürmann M; Suttorp N; Unterwalder N; Mönnich U; Meisel C; Wittke K; Volk HD; Scheibenbogen C; Kölsch U
J Clin Immunol; 2015 May; 35(4):361-5. PubMed ID: 25875701
[TBL] [Abstract][Full Text] [Related]
30. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
[TBL] [Abstract][Full Text] [Related]
31. Characterization of anti-canine cytokine monoclonal antibodies specific for IFN-gamma: effect of anti-IFN-gamma on renal transplant rejection.
Fuller L; Carreno M; Esquenazi V; Zucker K; Zheng S; Roth D; Burke G; Nery J; Asthana D; Olson L
Tissue Antigens; 1994 Mar; 43(3):163-9. PubMed ID: 8091415
[TBL] [Abstract][Full Text] [Related]
32. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.
Böttcher S; Ritgen M; Brüggemann M; Raff T; Lüschen S; Humpe A; Kneba M; Pott C
J Immunol Methods; 2005 Nov; 306(1-2):128-36. PubMed ID: 16181633
[TBL] [Abstract][Full Text] [Related]
34. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
35. The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII.
Fleit HB; Kobasiuk CD
J Leukoc Biol; 1991 Jun; 49(6):556-65. PubMed ID: 1709200
[TBL] [Abstract][Full Text] [Related]
36. IFN-gamma treated monocyte/macrophage phagocytosis of red cells sensitized with IgG1 and IgG3 Anti-D containing identical immunoglobulin variable region genes.
Perri D; Shabani F; Ziaeian G; Denomme GA
Transfus Apher Sci; 2008 Aug; 39(1):37-44. PubMed ID: 18614400
[TBL] [Abstract][Full Text] [Related]
37. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
[TBL] [Abstract][Full Text] [Related]
38. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
[TBL] [Abstract][Full Text] [Related]
39. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.
Behar G; Sibéril S; Groulet A; Chames P; Pugnière M; Boix C; Sautès-Fridman C; Teillaud JL; Baty D
Protein Eng Des Sel; 2008 Jan; 21(1):1-10. PubMed ID: 18073223
[TBL] [Abstract][Full Text] [Related]
40. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
